Ed Ergenzinger focuses his intellectual property law practice on patent procurement issues in the areas of biotechnology and pharmaceuticals. He works closely with clients on patent strategy and prosecution, freedom to operate issues, and general client counseling relating to technologies in the areas of biotechnology, pharmaceuticals, medical diagnostics, medical therapies, transgenic organisms, gene delivery, small molecule therapeutics, and pharmaceutical formulations. His scientific training includes research and graduate coursework in the areas of physiology, pharmacology, drug delivery systems, cellular and molecular biology, biochemistry, genetics and neurology.
Dr. Ergenzinger has served as an adjunct professor at Wake Forest University School of Law and has also taught a number of continuing legal education courses relating to intellectual property law. He is lead author or co-author on over 40 scientific and legal publications in venues such as Nature Neuroscience, Nature Reviews Neuroscience, Nature Biotechnology, Legal Times, The Scientist, BNA’s Patent, Trademark & Copyright Journal, and Stanford Technology Law Review.
Ed Ergenzinger focuses his intellectual property law practice on patent procurement issues in the areas of biotechnology and pharmaceuticals. He works closely with clients on patent strategy and prosecution, freedom to operate issues, and general client counseling relating to technologies in the areas of biotechnology, pharmaceuticals, medical diagnostics, medical therapies, transgenic organisms, gene delivery, small molecule therapeutics, and pharmaceutical formulations. His scientific training includes research and graduate coursework in the areas of physiology, pharmacology, drug delivery systems, cellular and molecular biology, biochemistry, genetics and neurology.
Dr. Ergenzinger has served as an adjunct professor at Wake Forest University School of Law and has also taught a number of continuing legal education courses relating to intellectual property law. He is lead author or co-author on over 40 scientific and legal publications in venues such as Nature Neuroscience, Nature Reviews Neuroscience, Nature Biotechnology, Legal Times, The Scientist, BNA’s Patent, Trademark & Copyright Journal, and Stanford Technology Law Review.
Dr. Ergenzinger is active in life sciences industry groups such as the Biotechnology Industry Organization (BIO) and Southeast BIO (SEBIO). For BIO, he serves on their Intellectual Property Counsels’ Committee and from 2003-2007 he chaired or co-chaired panels on patent legislation at the BIO International Conventions. These panels included Congressional leaders from the House Subcommittee on Courts, the Internet, and Intellectual Property, as well as officials from the USPTO and executives from Fortune 500 companies. In particular, the panel he co-chaired for BIO 2003 was selected for a special program on Capitol Hill for members of Congress and Congressional staff. For SEBIO, he currently serves on their board of directors and is a past chair of their marketing committee.
Dr. Ergenzinger earned his J.D. from Wake Forest University School of Law, where he was co-founder and editor-in-chief of the Wake Forest Intellectual Property Law Journal and the recipient of an American Bar Association Award for Excellence in the Study of Intellectual Property Law. He earned his Ph.D. in neuroscience at the Wake Forest University School of Medicine, where he was a National Institute of Mental Health Predoctoral Fellow. He earned his B.A. in biology and psychology, cum laude with honors, from Wake Forest University, where he was a Presidential Scholar.